KR20180009993A - Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient - Google Patents
Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient Download PDFInfo
- Publication number
- KR20180009993A KR20180009993A KR1020160092024A KR20160092024A KR20180009993A KR 20180009993 A KR20180009993 A KR 20180009993A KR 1020160092024 A KR1020160092024 A KR 1020160092024A KR 20160092024 A KR20160092024 A KR 20160092024A KR 20180009993 A KR20180009993 A KR 20180009993A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- enzyme
- extract
- wrinkles
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000037303 wrinkles Effects 0.000 title claims abstract description 42
- 239000004480 active ingredient Substances 0.000 title claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 title claims description 60
- 108090000790 Enzymes Proteins 0.000 title claims description 60
- 241001110062 Euphrasia officinalis Species 0.000 title abstract description 4
- 230000037394 skin elasticity Effects 0.000 claims abstract description 26
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 15
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 15
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims abstract description 5
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims abstract description 5
- 229940088598 enzyme Drugs 0.000 claims description 59
- 239000006210 lotion Substances 0.000 claims description 21
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 108010059892 Cellulase Proteins 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 229940106157 cellulase Drugs 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 235000020647 eyebright extract Nutrition 0.000 claims description 5
- 230000035764 nutrition Effects 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 108010056771 Glucosidases Proteins 0.000 claims description 2
- 102000004366 Glucosidases Human genes 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 108010038851 tannase Proteins 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000037331 wrinkle reduction Effects 0.000 abstract description 2
- 102000004157 Hydrolases Human genes 0.000 abstract 1
- 108090000604 Hydrolases Proteins 0.000 abstract 1
- 125000003147 glycosyl group Chemical group 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 34
- 108010035532 Collagen Proteins 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 17
- 210000002950 fibroblast Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- -1 ILs Proteins 0.000 description 12
- 102000016942 Elastin Human genes 0.000 description 10
- 108010014258 Elastin Proteins 0.000 description 10
- 108010050808 Procollagen Proteins 0.000 description 10
- 229920002549 elastin Polymers 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000004177 elastic tissue Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 4
- 241000201295 Euphrasia Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940114081 cinnamate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940107167 eyebright preparation Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 효소 처리된 아이브라이트 추출물을 유효성분으로 포함하는 피부 탄력 및 주름 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving skin elasticity and wrinkles comprising an enzyme-treated eyebrow extract as an active ingredient.
피부 주름 및 탄력은 피부 수분 함량, 콜라겐 함량 및 외부 환경에 대한 면역력 등 여러 가지 요소들에 의해 영향을 받는 것으로 알려져 있으며, 이중 피부의 주름 및 탄력에 가장 큰 영향을 미치는 것은 콜라겐의 생성량 및 콜라겐 분해 효소인 콜라게네이즈의 발현과 활성이다. Skin wrinkles and elasticity are known to be influenced by various factors such as skin moisture content, collagen content and immunity to the external environment. Among them, collagen production and collagen degradation Expression and activity of collagenase, an enzyme.
콜라겐은 피부 진피층에 존재하는데, 피부 전체 건조 중량의 약 70 내지 80%를 차지하는 엘라스틴과 함께 피부에 탄력을 부여하는 주요 성분으로 알려져 있다. 콜라겐은 자연 노화에 따른 세포활성 저하와 같은 내부 요인에 의해 감소되고, 여러 유해 환경에서의 스트레스 증가나 태양 광선에 의한 활성 산소 종의 증가와 같은 외부 요인에 의하여 생합성이 감소되거나, 분해가 촉진되고 있다.Collagen is present in the dermal layer of the skin and is known to be the main ingredient that imparts elasticity to the skin along with elastin, which accounts for about 70 to 80% of the dry weight of the skin. Collagen is reduced by internal factors such as decreased cell activity due to natural aging, and biosynthesis is reduced or accelerated by external factors such as increased stress in various harmful environments and increase of active oxygen species by sunlight have.
또한 활성산소종(reactive oxygen species, ROS)의 과생산은 UVB 노출 환경에서 보고된 바 있고, UVB 노출과 연관된 신호전달 체계는 MAPKs(mitogen activated protein kinases), ERK(extracellular signal-regulated kinase), p38 카이나아제, 및 JNK(c-Jun amino-terminal kinase) 등의 단백질과 관련되어 있는데, NF-κB 및 AP-1 전사인자의 발현증가를 유도한다. 이러한 AP-1 단백질은 MMP(matrix metalloproteinase) 유전자의 활성과 관련되어 있고, NF-κB 단백질은 인터루킨과 같은 전염증 사이토카인(proinflammatory cytokines)의 발현에 영향을 미친다. In addition, over-production of reactive oxygen species (ROS) has been reported in UVB exposure, and signaling pathways associated with UVB exposure include mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinases (ERK) Kinase, and JNK (c-Jun amino-terminal kinase), which induce increased expression of NF-κB and AP-1 transcription factors. This AP-1 protein is associated with the activity of the matrix metalloproteinase (MMP) gene, and the NF-κB protein affects the expression of proinflammatory cytokines such as interleukins.
노화된 피부에서 콜라겐 및 엘라스틴의 붕괴는 주로 MMP 단백질과 같은 그 분해 효소의 증가된 발현에 의해 야기된다. 또한, 전염증 사이토카인은 콜라겐의 합성을 방해하고, 콜라겐의 붕괴를 촉진시킨다. 타입 I 콜라겐은 연결 조직의 세포외 기질에서 가장 풍부한 단백질이다. 세포외 기질에는 타입 III, V, 및 VII 콜라겐, 엘라스틴, 프로테오글라이칸, 파이브로넥틴과 같은 다른 유형의 단백질을 포함한다. Collapse of collagen and elastin in aged skin is mainly caused by increased expression of its degrading enzyme such as MMP protein. In addition, proinflammatory cytokines interfere with the synthesis of collagen and promote collagen collapse. Type I collagen is the most abundant protein in the extracellular matrix of connective tissue. Extracellular matrix includes other types of proteins such as type III, V, and VII collagen, elastin, proteoglycan, and fibronectin.
타입 I 콜라겐 단백질의 발현 수준을 조절하는 것은 피부 광노화를 예방하는데 있어서 가장 중요한 인자이다. UVB의 조사는 TGF-β/Smad 신호전달 체계의 억제를 통해 피부 섬유아세포에서 콜라겐 전구체인 프로콜라겐(procollagen)의 발현을 감소시키게 된다. 또한, TGF-β1 신호전달 체계는 인간 피부 섬유아세포에서 세포외 기질의 합성을 조절하는 중요한 인자의 하나이다. Controlling the expression level of type I collagen protein is the most important factor in preventing skin photoaging. UVB irradiation reduces the expression of the collagen precursor procollagen in skin fibroblasts by inhibiting the TGF-β / Smad signaling pathway. In addition, the TGF-β1 signaling system is one of the important factors controlling the synthesis of extracellular matrix in human dermal fibroblasts.
따라서, AP-1 및 MAPKs 인자에 의해 조절되는 활성산소종(ROS)의 생성, 및 MMPs, ILs, TGF-β, 및 타입 I 프로콜라겐의 발현은 피부 노화, 피부의 탄력 감소 및 주름 증가에 관한 연구에 있어서 유용한 마커로 작용한다. Thus, the production of reactive oxygen species (ROS) regulated by AP-1 and MAPKs factors, and the expression of MMPs, ILs, TGF-ss, and type I procollagen are related to skin aging, They serve as useful markers in research.
콜라겐 감소를 저해하여 피부 주름개선에 효과가 있는 천연물질을 탐색하고자 하는 여러 가지 다양한 시도가 있었다. 예컨대, 콜라겐의 주름개선 효과를 이용하기 위하여 화장품 또는 연고 등과 같은 피부외용제 조성물에 콜라겐을 배합한 제품들이 출시되었으나, 이들 제품들은 콜라겐 자체를 피부 표면에 도포하는 것으로 고분자 물질인 콜라겐의 경피 흡수가 어려워 본질적인 주름개선 효과를 나타낼 수 없었다. There have been a variety of attempts to discover natural substances that are effective in reducing wrinkles by inhibiting collagen degradation. For example, in order to utilize the wrinkle-reducing effect of collagen, products containing collagen in a composition for external application for skin such as cosmetics or ointment have been marketed. However, since these products are coated on the skin surface, collagen, which is a polymer substance, It was not able to exhibit the essential wrinkle-improving effect.
이러한 문제를 해결하기 위하여 콜라겐합성 촉진물질에 대한 관심이 높아졌으며, 종래 알려진 콜라겐합성 촉진물질로는 비타민C, 레티노익산, 형질전환생장인자(transforming growth factor, TGF), 동물태반 유래의 단백질, 베툴린산, 클로렐라 추출물 등을 이용하는 것이 제안되었으나, 상기 물질은 피부 적용시 자극과 발적 등 안전성 문제로 사용량에 제한이 있거나 그 효과가 미미하여 실질적으로 주름개선 효과를 기대할 수 없다는 문제점이 있었다. 또한 대부분의 일반적인 천연물의 경우 원하는 수준의 효과를 얻기 위하여 피부에 적용되는 양이 통상적으로 피부에 적용가능한 수준을 넘어서기 때문에, 단순히 천연 추출물을 사용해서는 원하는 수준의 피부 주름 개선 및 탄력 증진의 효과를 얻을 수 없다. In order to solve this problem, there has been a growing interest in collagen synthesis promoting substances. Conventional collagen synthesis promoting substances include vitamin C, retinoic acid, transforming growth factor (TGF), animal placenta- It has been proposed that the above-mentioned substances have a limitation on the usage amount due to safety problems such as irritation and redness in skin application, and the effect thereof is insignificant, so that there is a problem that a wrinkle-reducing effect can not be expected substantially. In addition, since the amount of the skin to be applied to the skin generally exceeds the level applicable to the skin in order to obtain the desired level of effect in most of the natural products, the natural extract can be used to improve the desired level of skin wrinkles and elasticity I can not get it.
이러한 배경하에, 종래 주름개선 및 피부 탄력 증진용 조성물보다 생체에 안전하고 주름개선 및 피부 탄력 증진 효과가 높은 새로운 조성물의 개발이 절실히 요구되고 있다.Under these circumstances, there is a desperate need to develop a new composition which is more safe for living body and has better wrinkle and skin elasticity than compositions for improving wrinkles and skin elasticity.
본 발명의 목적은 당가수분해 효소 처리된 아이브라이트 추출물을 유효성분으로 포함하는 피부 탄력 및 주름 개선용 조성물을 제공하는 데 있다.It is an object of the present invention to provide a composition for improving skin elasticity and wrinkles, which comprises an ibrite extract obtained by hydrolyzing sugar chains as an active ingredient.
본 발명자들은 피부 주름 개선 및 탄력 증진의 효과를 극대화할 수 있는 화장료 조성물의 주원료에 관하여 연구하던 중, 아이브라이트 추출물에 당가수분해 효소를 처리하는 경우 인간 섬유아세포(human dermal fibroblasts, NHDFs)에서 광노화를 비롯한 피부 노화 및 주름 증진에 대한 뛰어난 개선 효과가 있음을 확인하고, 본 발명을 완성하였다.The inventors of the present invention have been studying the main ingredients of a cosmetic composition capable of maximizing the effect of improving skin wrinkles and improving the elasticity. In the case of treating the sugar chain hydrolysing enzyme with the ibrite extract, the dermal fibroblasts (NHDFs) The present invention has been completed upon confirming that there is an excellent improvement effect on aging of skin and promotion of wrinkles.
본 발명은 당가수분해 효소 처리된 아이브라이트 추출물을 유효성분으로 포함하는 피부 탄력 및 주름 개선용 조성물을 제공한다. The present invention provides a skin elasticity and wrinkle-improving composition comprising an ibrite extract which has been treated with a saccharide-hydrolyzing enzyme as an active ingredient.
본 발명에 따른 피부 탄력 및 주름 개선용 조성물은 피부에 적용시 안전성에 문제가 없으며, 항산화 효과, MMP-1 단백질 발현 억제 효과, 타입 Ⅰ 프로콜라겐의 생성 증진 효과 등을 통해, 피부 주름의 발생을 예방하고, 손상된 피부의 주름을 개선하며, 피부 탄력을 증진, 특히 자외선에 의한 피부 주름 및 피부 탄력 저하를 개선시킴으로써 피부 탄력 및 주름 개선에 현저한 효과를 보인다. The composition for improving skin elasticity and wrinkles according to the present invention has no problem in safety when applied to the skin, and has an antioxidative effect, an inhibitory effect on MMP-1 protein expression, and an effect of promoting the production of type I pro- And improve wrinkles of damaged skin, improve skin elasticity, especially wrinkle of skin caused by ultraviolet rays, and decrease skin elasticity, thereby remarkably improving skin elasticity and wrinkle.
본 발명에서 사용되는 용어 "아이브라이트(Euphrasia officinalis) "는 서아시아와 유럽이 원산지인 허브로, 높이 약 20cm까지 자란다. 잎들 사이에서 꽃이 피는데, 꽃은 크기가 작고 보라빛을 띤 흰색이다. 직접 채취할 수도 있고 국내외에서 손쉽게 구매할 수도 있다. As used herein, the term " Euphrasia officinalis " "Is a herb originating in West Asia and Europe and growing up to about 20 cm in height. Flowers bloom between the leaves, the flowers are small in size and purple, they can be picked up directly or bought easily at home and abroad.
본 발명에서 사용되는 용어, "추출물"은 식물의 추출 처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 본 발명의 상기 추출물은 바람직하게 추출 후 건조 분말 형태로 제조되어 사용될 수 있다. The term "extract" used in the present invention refers to an extract obtained by extracting a plant, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a controlled preparation or a purified product of the extracted solution, Extracts themselves and extracts of all formulations which can be formed using extracts. The extract of the present invention can be preferably prepared in the form of a dry powder after extraction.
본 발명에서 사용되는 용어, "당가수분해 효소(glycolytic enzyme)"는 해당 반응을 촉매하는 효소를 모두 포함하며, 셀룰로오스, 아밀로오스, 탄닌, 펙틴 등의 올리고당을 분해하는 효소를 말한다. As used herein, the term "glycolytic enzyme" refers to an enzyme that contains all the enzymes that catalyze the reaction and decomposes oligosaccharides such as cellulose, amylose, tannin, and pectin.
바람직한 당가수분해 효소는 셀룰라아제(cellulase), 펙티나아제(pectinase), 글루코시다아제(glucosidase) 및 탄나아제(tannase)로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있으며, 보다 바람직하게 셀룰라아제이다. 상기 효소들은 단독으로 사용하거나, 또는 이들 효소들을 복합 처리하여 사용할 수도 있다. 본 발명에서 제시하는 당가수분해 효소 처리된 아이브라이트 추출물은 특별한 언급이 없는 한, 상기 예시된 효소 이외에도 해당 반응을 촉매하는 당가수분해 효소로 처리된 아이브라이트 추출물을 모두 포함하며, 주름 개선 및 피부 탄력 증진을 위한 소재로 사용될 수 있다.The preferred saccharide-hydrolyzing enzyme may be any one or more selected from the group consisting of cellulase, pectinase, glucosidase and tannase, more preferably a cellulase. These enzymes can be used alone, or they can be used in combination. The diabody extract treated with the sugar chain hydrolyzing enzyme proposed in the present invention includes all of the ibrite extract treated with the sugar chain hydrolyzing enzyme catalyzing the reaction in addition to the above exemplified enzymes, It can be used as a material for improving elasticity.
본 발명에서 사용되는 용어 "주름"이란, 피부가 쇠하여 생긴 잔줄을 의미하는데, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐과 엘라스틴의 감소, 외부환경 등에 의해 유발될 수 있다.As used herein, the term "wrinkle " refers to a scarred skin caused by a genetic cause, reduced collagen and elastin present in the skin dermis, and an external environment.
본 발명에서 사용되는 용어 "주름 개선"이란, 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.As used herein, the term "wrinkle reduction" refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명에서 사용되는 용어 "피부 탄력"이란, 진피층에 존재하는 엘라스틴(elastin)으로 구성된 탄력섬유에 의해 나타나는 탄성을 말하며, 이러한 탄력섬유는 고무와 같이 매우 낮은 탄성계수를 가지고 있어서, 작은 힘에 의해서도 쉽게 변형되고, 또 그 힘이 제거되었을 때는 쉽게 원형으로 되돌아 온다. 또한, 탄력섬유는 엘라스틴이라는 무정형의 기질에 미원섬유(microfibrils)들이 박혀 있는 형태를 띠고 있으며, 엘라스틴은 라이신에서 유래한 데스모신(desmosine)과 아이소데스모신(isodesmosine)이라는 탄력섬유에서만 발견되는 아주 톡특한 아미노산으로 구성된 단백질이다. 이러한 데스모신과 아이소데스모신 등은 긴 펩타이드사슬안에서 가교(cross-links)를 형성하고 있는데, 이러한 구조가 엘라스틴으로 하여금 고무와 같은 성질을 갖게 한다.As used herein, the term "skin elasticity" refers to elasticity exhibited by elastic fibers composed of elastin existing in the dermal layer. Such elastic fibers have a very low elastic modulus such as rubber, It easily deforms, and when the force is removed, it easily returns to the original shape. In addition, the elastic fibers have a form in which microfibrils are embedded in an amorphous matrix called elastin, and elastin is a protein that is found only in elastic fibers such as desmosine and isodesmosine derived from lysine, It is a protein composed of one amino acid. These desmosins and isodesmesynes form cross-links in long peptide chains, which makes elastin behave like a rubber.
본 발명에서 사용되는 용어 "피부 탄력 개선"이란 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다.As used herein, the term "improvement of skin elasticity" means that elastic fibers composed of elastin are present together with collagen fibers called collagen, and elastic elasticity is maintained in a state where elastin and collagen are sufficiently present.
본 발명에 있어서, 추출물의 제조는 용매 하의 아이브라이트에 당가수분해 효소 처리하여 제조될 수 있다. In the present invention, the preparation of the extract can be prepared by digestion with a sugar-water-degrading enzyme to an ibrite under a solvent.
상기 아이브라이트의 추출 용매는 물, 탄소수 1 내지 4의 알코올 또는 이의 혼합물, 바람직하게는 물, 에탄올, 에탄올 수용액을 사용하는 것이 좋으나, 이에 한정되는 것은 아니다. 상기 추출 용매의 양은 아이브라이트의 총중량의 0.5 내지 15 배로 한다. 또한, 필요에 따라 차광 및/또는 가온(예를 들어, 온침) 조건 하에서 수행될 수도 있다. 상기 용매 하에 당가수분해 효소는 아이브라이트 총중량에 대하여 0.5 중량 % 내지 5 중량 %로 포함될 수 있으며, 1시간 내지 10시간 동안 40 내지 55 ℃로 반응을 통해 추출될 수 있고, 분리된 상등액은 감압농축을 통해서 액상 또는 분말 형태의 추출물로 제조될 수 있으며, 이를 동결건조하여 분말형태로 제조될 수 있다. 본 발명의 추출물에 있어서 추출 부위는 그 제한이 없지만, 바람직하게 아이브라이트의 잎 또는 줄기를 사용할 수 있다. The extraction solvent for the ibrite is preferably water, an alcohol having 1 to 4 carbon atoms or a mixture thereof, preferably water, ethanol or ethanol aqueous solution, but is not limited thereto. The amount of the extraction solvent is 0.5 to 15 times the total weight of the ibrite. It may also be carried out under shading and / or warming (e.g., warming) conditions, if desired. The sugar-free water-degrading enzyme under the solvent may be contained in an amount of 0.5 to 5% by weight based on the total weight of the ibrite, and may be extracted from the reaction at 40 to 55 ° C for 1 hour to 10 hours. The separated supernatant is concentrated under reduced pressure And may be prepared into a powder form by lyophilization. In the extract of the present invention, the extraction site is not limited, but preferably leaves or stems of ibrite can be used.
본 발명의 피부 탄력 및 주름 개선용 조성물에 함유된 효소 처리된 아이브라이트 추출물은 그 자체로 피부 주름을 제거하는 효과가 있으며, 바람직하게 본 발명에 있어서, 상기 당가수분해 효소 처리 아이브라이트 추출물은 조성물 총중량에 대하여 0.001% ~ 10중량%의 양으로 포함될 수 있다. The enzyme-treated ibrite extract contained in the skin elasticity and wrinkle-improving composition of the present invention has an effect of removing skin wrinkles by itself. Preferably, in the present invention, the diabody extract treated with the sugar chain- May be contained in an amount of 0.001% to 10% by weight based on the total weight.
또한 본 발명의 조성물은 기존에 알려진 피부 주름 예방 및 개선에 효과가 있다고 공지된 물질들과 혼합하여 사용하는 경우에도 피부 탄력 및 주름 개선 효과를 지속적으로 유지할 수 있다. In addition, the composition of the present invention can maintain skin elasticity and wrinkle improving effect even when it is mixed with known substances that are known to be effective for preventing and improving wrinkles of skin.
상기 피부 탄력 및 주름 개선에 효과가 있는 물질로는 이에 제한되지는 않으나, 캐모마일 꽃 추출물, 로즈마리 잎 추출물, 할미꽃 잎 추출물, 어스니어 추출물, 인삼 추출물, 유카리투스 잎 추출물, 제라늄 꽃 추출물, 고삼 추출물 유칼립투스 추출물, 타임 추출물, 아이브라이트 추출물, 쐐기풀 추출물, 야로우 추출물, 클로브 추출물, 펜넬 추출물, 파파야잎 추출물, 및 해바라기 추출물 등이 있다. 이외에도 본 발명의 화장료 조성물은 수용성 비타민, 지용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스 등을 더 포함할 수 있다.Materials effective for improving skin elasticity and wrinkles include, but are not limited to, chamomile flower extract, rosemary leaf extract, horticulture leaf extract, earth flower extract, ginseng extract, eucalyptus leaf extract, geranium flower extract, Extract, Time Extract, Ibrite Extract, Nettle Extract, Yarrow Extract, Clove Extract, Fennel Extract, Papaya Leaf Extract, and Sunflower Extract. In addition, the cosmetic composition of the present invention may further comprise water-soluble vitamins, fat-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
본 발명의 피부 탄력 및 주름 개선용 조성물에는 상기 필수 성분과 더불어 필요에 따라 화장품학적으로 허용가능한 담체를 추가로 포함하여 배합될 수 있다. 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 자외선 흡수제, pH 조정제, 향료, 혈행 촉진제, 냉감제, 제한제, 정제수 등을 들 수 있다.The composition for improving skin elasticity and wrinkles of the present invention may further comprise a cosmetically acceptable carrier in addition to the above essential components, if necessary. Examples of the compounding ingredient to be added include a preservative component, a moisturizer, an emollient, an ultraviolet absorber, a pH adjuster, a flavor, a blood circulation accelerator, a cold agent, a limiting agent and purified water.
상기 유지 성분으로는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the above-mentioned sustaining component include ester-based oils, hydrocarbon-based oils, silicone-based oils, fluorine-based oils, animal oils, and plant oils.
상기 보습제로는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers.
상기 에몰리엔트제로는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollients include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid, and lanolin fatty acid cholesteryl ester.
상기 자외선 흡수제로는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of the ultraviolet absorber include para-aminobenzoic acid, ethyl paranobenzoate, amyl paranobenzoate, octyl paranobenzoate, ethylene glycol salicylate, phenyl salicylate, benzyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, Benzyl cinnamate, 2-ethoxyethyl paratomethoxy cinnamate, octyl paratomethoxy cinnamate, mono-2-ethylhexane glyceryl diflamamethoxycinnamate, isopropyl paratumoxycinnamate, diisopropyl-diisopropyl cinnamate ester mixture , Urocannic acid, ethyl urocanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and salts thereof, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxy Benzophenone, tetrahydroxybenzophenone, 4-tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino-p- (carbo-2'-ethylhexyl- -1,3,5-triazine, 2- (2-H And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
상기 pH 조정제로는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjusting agent include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하다.The components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.
본 발명의 조성물을 함유하여 제조된 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic preparation prepared by containing the composition of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.
또한, 본 발명의 상기 조성물에 포함되는 성분은 유효성분으로서 상기 성분 이외에 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 안료 및 천연향료와 같은 통상적인 보조제 및 담체를 더 포함할 수 있다.In addition, the components contained in the composition of the present invention may contain, as an active ingredient, components commonly used in compositions other than the above components, for example, conventional auxiliary agents such as stabilizers, pigments and natural flavors, and carriers .
본 발명의 조성물은 피부 탄력 증진 및 피부 주름 개선 효과를 갖는 화장품 또는 세안제 등에 다양하게 이용될 수 있다. The composition of the present invention can be used variously in cosmetics or facial washers having skin elasticity enhancement and skin wrinkle improving effect.
본 발명의 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩 등과 같은 화장품류와 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등이 있다.Examples of products to which the composition of the present invention can be added include a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, Cosmetics such as foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, , Propane, such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 피부 탄력 및 주름 개선용 조성물은 항산화 효과, MMP-1 단백질 발현 억제 효과, 타입 Ⅰ 프로콜라겐의 생성 증진 효과 등을 통해, 피부 주름의 발생을 예방하고, 손상된 피부의 주름을 개선하며, 피부 탄력을 증진시킴으로써 피부 탄력 및 주름 개선에 현저한 효과를 보인다. INDUSTRIAL APPLICABILITY The composition for improving skin elasticity and wrinkles according to the present invention can prevent the occurrence of wrinkles of the skin, improve the wrinkles of the damaged skin, and improve the elasticity of the skin through the antioxidative effect, the MMP-1 protein expression inhibiting effect, By enhancing skin elasticity, it shows remarkable effect on skin elasticity and wrinkle improvement.
도 1은 당가수분해 효소 처리된 아이브라이트 추출물의 DPPH 라디칼 억제 활성을 나타낸다.
도 2는 당가수분해 효소 처리된 아이브라이트 추출물의 인간섬유아세포에서 MMP-1 단백질의 발현 감소 효과를 나타낸다.
도 3은 당가수분해 효소 처리된 아이브라이트 추출물의 UVB 조사된 인간섬유아세포에서 MMP-1 단백질의 발현 감소 효과를 나타낸다.
도 4는 당가수분해 효소 처리된 아이브라이트 추출물의 인간섬유아세포에서 타입 I 프로콜라겐 단백질의 발현 증진 효과를 나타낸다.
도 5는 당가수분해 효소 처리된 아이브라이트 추출물의 UVB 조사된 인간섬유아세포에서 타입 I 프로콜라겐 단백질의 발현 증진 효과를 나타낸다.
도 6은 당가수분해 효소처리 아이브라이트 추출물과 효소처리되지 않은 아이브라이트 추출물의 크로마토그래피 분석 결과를 나타낸다. Fig. 1 shows DPPH radical scavenging activity of the ibrite extract treated with sugar chain hydrolysis enzyme.
FIG. 2 shows the effect of reducing the expression of MMP-1 protein in human fibroblasts of the ibriye extract treated with sugar chain hydrolysing enzyme.
FIG. 3 shows the effect of reducing the expression of MMP-1 protein in UVB-irradiated human fibroblasts of an ibright extract treated with a sugar chain-hydrolyzing enzyme.
Fig. 4 shows the effect of enhancing the expression of type I procollagen protein in human fibroblasts of an ibrite extract treated with a saccharide-hydrolyzing enzyme.
FIG. 5 shows the effect of enhancing the expression of type I procollagen protein in UVB-irradiated human fibroblasts of the ibriate extract treated with the sugar chain hydrolysing enzyme.
Fig. 6 shows the chromatographic analysis results of the sugar-added water-soluble enzyme-treated eyebrow extract and the non-enzyme-treated eyebrow extract.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.
실시예Example 1: One: 당가수분해Party gets pollinated 효소 처리된 Enzyme-treated 아이브라이트Eye Bright 추출물의 제조 Preparation of extract
아이브라이트(Euphrasia officinalis) 전초 (잎 줄기) 1kg을 정제수로 세척하고 건조시킨 다음, 분쇄하고 세말화하여 분말을 얻었다. 분말화된 아이브라이트에 10L의 증류수를 가한 후, 1M HCl과 1M NaOH를 이용하여 용액이 pH 5-8 사이가 되도록 조절하였다. 여기에 효소로 셀룰라아제를 아이브라이트 분말의 중량 대비 1%로 첨가하였다. 그리고, 셀룰라아제가 첨가된 용액을 항온수조에 넣고 50℃에서 3시간 동안 교반하여 효소와 반응시켰다. 효소와 반응시킨 반응물을 여과하고, 그 상등액을 동결 건조하여 실시예로 이용하였다. 1 kg of Euphrasia officinalis outpost (leaf stem) was washed with purified water and dried, followed by pulverization and cementation to obtain a powder. 10 L of distilled water was added to the powdered Ibolite, and the solution was adjusted to pH 5-8 using 1 M HCl and 1 M NaOH. Cellulase was added thereto as an enzyme in an amount of 1% based on the weight of the ibrite powder. Then, the solution containing the cellulase was added to a constant temperature water bath and stirred at 50 ° C for 3 hours to react with the enzyme. The reaction product reacted with the enzyme was filtered, and the supernatant was used as an example by lyophilization.
상기와 같은 방식으로 추출하되, 셀룰라아제 효소로 처리되지 않은 아이브라이트 추출물을 동결 건조하여 비교예로 사용하였다. The iBlue extract which had not been treated with the cellulase enzyme was lyophilized and used as a comparative example.
실시예Example 2: 2: 당가수분해Party gets pollinated 효소처리된Enzyme-treated 아이브라이트Eye Bright 추출물의 항산화 효과 확인 Identification of antioxidative effect of extract
DPPH (1,1-diphenyl-2-picrylhydrazyl, Sigma, USA)의 환원력을 측정함으로써 효소처리된 아이브라이트 추출물의 항산화 효과를 확인하였다. DPPH의 환원력은 Sang S 등, J.Agric. Food Chem. 50(8), p2459-2463, 2002에 기재된 방법에 따라 수행하였으며, 상기 실시예 1에 따른 당가수분해 효소 처리된 아이브라이트 추출물을 처리함으로써 측정하였다. DPPH (1,1-diphenyl-2-picrylhydrazyl, Sigma, USA), and the antioxidative effect of the enzyme-treated ibrite extract was confirmed. The reducing power of DPPH is reported in Sang S et al., J. Agric. Food Chem. 50 (8), p2459-2463, 2002, and the sugar according to the above Example 1 was subjected to treatment with the ibrite extract treated with the water-degrading enzyme.
메탄올에 녹인 0.2 mM DPPH 용액 180 ul와 증류수 20 ul에 녹인 아이브라이트 추출물(음성 대조군), 당가수분해 효소 처리된 아이브라이트 추출물 및 알부틴(양성대조군)(100 및 250 ㎍/㎖)을 96-웰 마이크로플레이트에 넣고 37℃에서 30 분간 배양한 후, 환원된 DPPH의 양을 분광 광도계(Precision microplate reader; Molecular Devices, VersaMax)를 이용하여 520 nm에서 흡광도를 측정하여 시료를 가하지 않는 무첨가 대조군과 활성을 비교하여 3 반복으로 수행하였으며, 그 결과를 도 1에 나타내었다.(Negative control), 180 μl of a 0.2 mM DPPH solution dissolved in methanol and 20 μl of distilled water, an ibrite extract and an arbutin (positive control) (100 and 250 μg / ml) After incubation at 37 ° C for 30 min, the amount of reduced DPPH was measured at 520 nm using a spectrophotometer (Precision Microplate Reader, Molecular Devices, VersaMax). The results are shown in Fig.
도 1에서 확인되는 바와 같이, 당가수분해 효소 처리된 아이브라이트 추출물은 아이브라이트 추출물에 비해 각각 50, 100, 및 250㎍/㎖ 용량 처리시, 111%, 114% 및 154% 개선된 우수한 항산화 효과가 확인되었으며, 이러한 항산화 효과의 수치들은 양성대조군인 알부틴과 비교하였을 때도 크게 우수한 효과임이 확인되었다. As can be seen in Figure 1, the glucose-hydrolysed enzyme-treated iiburide extracts showed 111%, 114% and 154% improved, respectively, at 50, 100, and 250 μg / And the antioxidant effect was significantly superior to that of the positive control group, arbutin.
실시예Example 3. 3. 당가수분해Party gets pollinated 효소처리된Enzyme-treated 아이브라이트Eye Bright 추출물의 Extract MMPMMP -1 단백질 합성 저해 효과 확인-1 protein synthesis inhibitory effect
MMP-1 단백질의 합성 저해 효과를 확인함으로써 본 발명 추출물의 피부 주름 개선 및 탄력 증진 효과를 확인하였다. And confirming the effect of inhibiting the synthesis of MMP-1 protein, thereby improving the skin wrinkles and improving the elasticity of the extract of the present invention.
40 mm 세포 배양 접시에 2 ㎖의 DMEM 배양액을 넣고, 인간섬유아세포를 약 1.2x105 개의 농도로 접종한 후, 37 ℃, 5 % CO2 환경에서 24시간 동안 배양하였다. 그 후 일부 실험군에 대해서는 UVB 처리가 없었으며 별개의 실험군에 대해서는 UVB를 144 mJ/cm2 조건으로 조사한 후 실시예 1에서 제조된 당가수분해 효소 처리된 아이브라이트 추출물(각각 10 및 100 ㎍/㎖)을 포함한 배지로 교체하여 3 일간 배양하였다. 이후 배양액을 회수(harvest)하여 4 ℃, 7500 rpm 환경에서 5분간 원심분리(centrifuge)하여 ELISA 방법을 이용하여 MMP-1(Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA)의 단백질 발현량 변화를 확인하여, 그 결과를 도 2 및 도 3에 나타내었다.2 ml of DMEM culture medium was added to a 40 mm cell culture dish, human fibroblasts were inoculated at a concentration of about 1.2 x 10 5 , and then cultured in a 5% CO 2 environment at 37 ° C for 24 hours. Thereafter, UVB treatment was not performed for some experimental groups, and UVB was applied at 144 mJ / cm 2 for separate test groups. After treatment with the diabody extract (10 and 100 μg / ml, respectively) ), And cultured for 3 days. The cultures were then harvested and centrifuged at 7500 rpm for 5 minutes at 4 ° C to obtain MMP-1 (Human Total MMP-1 kit, R & D Systems, Inc., Minneapolis, ). The results are shown in FIG. 2 and FIG. 3. FIG.
도 2는 자외선 조사 없는 인간섬유아세포 실험에서의 결과를 나타낸다. 도 2에서 확인되는 바와 같이, 당가수분해 효소 처리된 아이브라이트 추출물 처리군은 MMP-1 단백질의 생성이 농도 의존적으로 크게 억제되며, 이러한 효과는 효소 처리되지 않은 아이브라이트 추출물을 처리한 군과 비교할 때 월등히 우수한 것이 확인되었다. 즉, 효소 처리된 군에서는 각각 1, 10, 및 100㎍/㎖ 용량에서 14%, 26%, 및 47%, 개선된 MMP-1 단백질의 생성 저해 효과를 나타내어, 효소 처리된 아이브라이트 추출물의 MMP-1 단백질 생성억제 효과가 더욱 큰 것으로 나타났다. Figure 2 shows the results in a human fibroblast experiment without ultraviolet irradiation. As shown in FIG. 2, in the group treated with the ibbrite extract treated with glucose-hydrolyzing enzyme, the production of MMP-1 protein was significantly inhibited in a concentration-dependent manner, and this effect was compared with the group treated with the enzyme-treated ibright extract , It was confirmed that it was superior. In other words, the enzyme-treated group showed 14%, 26%, and 47% inhibition of the production of MMP-1 protein at 1, 10, and 100 μg / -1 protein production inhibitory effect.
또한, 도 3은 자외선 조사된 인간섬유아세포 실험에서의 결과를 나타낸다. 도 3에서 확인되는 바와 같이, 144mJ/cm2 용량으로 자외선 조사 처리한 인간섬유아세포는 자외선 무처리 군에 비해 MMP-1 단백질의 생성이 6배 증가하였다. 자외선 조사 처리로 인한 MMP-1 단백질의 생성 증가는 당가수분해 효소 처리된 아이브라이트 추출물 처리군에 의해 현저히 감소되었다. 이러한 MMP-1 감소 효과는 효소 처리되지 않은 군과 비교할 때 월등한 효과를 나타내는데, 각각 1, 10, 및 100㎍/㎖ 용량에서 36%, 32%, 및 23%, 개선된 MMP-1 단백질의 생성 저해 효과를 나타내었다.3 shows the results in an ultraviolet irradiated human fibroblast experiment. As can be seen in FIG. 3, human fibroblasts irradiated with ultraviolet rays at a dose of 144 mJ / cm < 2 > 6 times. The increase in the production of MMP-1 protein by ultraviolet irradiation treatment was significantly reduced by the group treated with the ibrite extract treated with water-soluble enzyme. These reductions in MMP-1 were superior to those in the untreated group, with 36%, 32%, and 23% improved at 1, 10, and 100 μg / MMP-1 < / RTI >
상기 결과를 통해, 본 발명의 당가수분해 효소 처리된 아이브라이트 추출물은 주름생성의 원인이 되는 MMP-1 단백질의 생성을 효과적으로 억제하여 피부 주름 개선 및 탄력 증진에 효과적임을 확인하였다. From the above results, it has been confirmed that the ibrite extract treated with the sugar chain of the present invention effectively inhibits the production of MMP-1 protein, which is a cause of wrinkle formation, and is effective in improving skin wrinkles and elasticity.
실시예Example
4. 4.
당가수분해Party gets pollinated
효소처리된Enzyme-treated
아이브라이트
타입 1 프로콜라겐 단백질의 합성 촉진 효과를 확인함으로써 본 발명 추출물의 피부 주름 개선 및 탄력 증진 효과를 확인하였다. Confirming the promoting effect of the
40 mm 세포 배양 접시에 2 ㎖의 DMEM 배양액을 넣고, 인간섬유아세포를 약 1.2x105 개의 농도로 접종한 후, 37 ℃, 5 % CO2 환경에서 24시간 동안 배양하였다. 그 후 일부 실험군에 대해서는 UVB 처리가 없었으며 별개의 실험군에 대해서는 UVB를 144 mJ/cm2 조건으로 조사한 후, 실시예 1에서 제조된 당가수분해 효소 처리된 아이브라이트 추출물(100 ㎍/㎖)을 포함한 배지로 교체하여 3일간 배양하였다. 이후 배양액을 회수(harvest)하여 4 ℃, 7500 rpm 환경에서 5분간 원심분리(centrifuge)하여 ELISA 방법을 이용하여 타입 1 프로콜라겐(Procollagen Type I C Peptide EIA Kit, Takara, Shiga, Japan)의 단백질 발현량 변화를 확인하여, 그 결과를 도 4 및 도 5에 나타내었다. 2 ml of DMEM culture medium was added to a 40 mm cell culture dish, human fibroblasts were inoculated at a concentration of about 1.2 x 10 5 , and then cultured in a 5% CO 2 environment at 37 ° C for 24 hours. Thereafter, UVB treatment was not performed for some experimental groups, and UVB was applied at 144 mJ / cm 2 for separate test groups. Then, the sugar-added water-soluble enzyme-treated ibright extract (100 μg / ml) And the cells were cultured for 3 days. Then, the culture solution was harvested and centrifuged at 7500 rpm for 5 minutes at 4 ° C. The protein expression level of
도 4는 자외선 조사 없는 인간섬유아세포 실험에서의 결과를 나타낸다. 도 4에서 확인되는 바와 같이, 자외선 조사 없는 인간섬유아세포 실험에서 당가수분해 효소 처리된 아이브라이트 추출물 처리군은 타입 1 프로콜라겐 단백질의 생성을 농도 의존적으로 증가시키고 있음을 알 수 있었다. 이러한 효과는 효소 처리되지 않은 아이브라이트 추출물을 처리한 군과 비교할 때 월등히 우수하였으며, 효소 처리되지 않은 아이브라이트 추출물 처리 군 대비, 효소 처리된 군에서는 100㎍/㎖ 용량에서 127% 개선된 타입 1 프로콜라겐 단백질의 생성 증가를 나타내어, 효소 처리된 아이브라이트 추출물 처리시 타입 1 프로콜라겐 단백질의 생성 증가 효과가 더욱 큰 것으로 나타났다. Figure 4 shows the results in human fibroblast experiments without ultraviolet radiation. As can be seen in FIG. 4, in the human fibroblast-free experiment without ultraviolet irradiation, it was found that the group treated with the ibrite extract treated with glucose-hydrolyzing enzyme increased the production of
또한, 도 5는 자외선 조사된 인간섬유아세포 실험에서의 결과를 나타낸다. 도 5에서 확인되는 바와 같이, 144mJ/cm2 용량으로 자외선 조사 처리한 인간섬유아세포는 자외선 무처리 군에 비해 타입 1 프로콜라겐 단백질의 생성이 2.2배 감소하였다. 이렇게 자외선 조사 처리로 인한 타입 1 프로콜라겐 단백질의 생성 감소는 효소처리 아이브라이트 추출물의 처리에 의해서 다시 크게 증가하는 것이 확인되었다. 이러한 당가수분해 효소 처리된 아이브라이트 추출물 처리군은 효소 처리되지 않은 군과 비교할 때 월등한 증가 효과를 나타내는데, 각각 10 및 100㎍/㎖ 용량에서 110% 및 139% 개선된 타입 1 프로콜라겐 단백질의 생성 증가 효과를 나타내었다. Fig. 5 also shows the results in an ultraviolet irradiated human fibroblast experiment. As can be seen from FIG. 5, the production of
상기와 같은 결과를 통해, 본 발명의 당가수분해 효소 처리된 아이브라이트 추출물을 포함하는 조성물이 TGF-β/Smad 신호전달체계에 작용하여 타입 1 프로콜라겐의 생성을 촉진시키고, 콜라겐 분해 효소인 MMP-1의 발현을 억제하는 작용을 통해, 주름 생성을 효과적으로 개선하고 탄력 증진에 현저한 효과가 있음을 확인하였다. As a result, the composition comprising the sugar chain hydrolytic enzyme-treated ibrite extract of the present invention acts on the TGF-β / Smad signal transduction system to promote the production of
실시예Example 5. 5. 당가수분해Party gets pollinated 효소 처리된 Enzyme-treated 아이브라이트Eye Bright 추출물과 Extract and 아이브라이트Eye Bright 추출물의 성분 비교 분석 Comparative analysis of components of extract
상기 실시예 1 및 비교예로 제조한 추출물 성분을 크로마토그래피(Dionex Chromelon Chromatography, Dionex, USA) 장비를 이용하여 분석하였다. 컬럼(Column)은 Sunfire C18(워터스, 4.6x250mm, 5micron)을 사용하였고, 컬럼 오븐 온도는 30ㅀC, 검출기는 280nm 인젝션 볼륨 10uL, 유속 1.0mL/min으로 분석하였다.The extract components prepared in Example 1 and Comparative Example were analyzed by chromatography (Dionex Chromelon Chromatography, Dionex, USA). The column was a Sunfire C18 (Waters, 4.6x250mm, 5micron), column oven temperature 30 ㅀ C, detector 280nm injection volume 10uL, flow rate 1.0mL / min.
그 결과를 도 6에 나타내었다. The results are shown in Fig.
도 6에 나타낸 바와 같이, 실시예 1의 당가수분해 효소 처리한 아이브라이트 추출물(파란색 라인)이 효소 처리하지 않은 아이브라이트 추출물(검은색 라인)에 비해 주요성분의 함량이 크게 변화된 것이 확인되었다. 특히, HPLC 분석 결과에 따르면 polyphenol 성분이 크게 증가함으로써 주름 개선에 우수한 효과를 보일 수 있음이 확인된다. As shown in Fig. 6, it was confirmed that the content of the main component was significantly changed in the ibrite extract (blue line) treated with the sugar chain hydrolysis enzyme of Example 1, compared with the ibrite extract (black line) not subjected to the enzyme treatment. Especially, according to the results of HPLC analysis, it is confirmed that the polyphenol component is greatly increased, and thus, the wrinkle improvement is excellent.
제형예Formulation Example 1: One: 당가수분해Party gets pollinated 효소 처리된 Enzyme-treated 아이브라이트Eye Bright 추출물을 함유한 화장수 제조 Manufacture of lotion containing extract
당가수분해 효소처리된 아이브라이트 추출물(실시예 1)을 함유한 화장수(스킨로션)를 하기의 [표 1]의 함량으로 1kg을 제조하였다.1 kg of lotion (skin lotion) containing the ibriel extract (Example 1) treated with the sugar-water-degrading enzyme was prepared by the content of [Table 1] shown below.
[표 1] 당가수분해 효소처리된 아이브라이트 추출물을 함유한 화장수 조성[Table 1] Composition of lotion containing water-decomposable enzyme-treated ibright extract
제형예Formulation Example 2: 2: 당가수분해Party gets pollinated 효소처리된Enzyme-treated 아이브라이트Eye Bright 추출물을 함유한 Extract-containing 영양로션Nutrition Lotion 제조 Produce
당가수분해 효소처리된 아이브라이트 추출물 (실시예 1)을 함유한 영양로션을 하기의 [표 2]의 함량으로 1kg을 제조하였다. 1 kg of nutritional lotion containing an ibriel extract (Example 1) treated with a sugar-water-degrading enzyme was prepared by the content of [Table 2] shown below.
[표 2] 당가수분해 효소처리된 아이브라이트 추출물을 함유한 영양로션 조성[Table 2] Nutritional lotion composition containing an ibriate extract treated with a sugar-water-degrading enzyme
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160092024A KR20180009993A (en) | 2016-07-20 | 2016-07-20 | Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160092024A KR20180009993A (en) | 2016-07-20 | 2016-07-20 | Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180009993A true KR20180009993A (en) | 2018-01-30 |
Family
ID=61070554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160092024A KR20180009993A (en) | 2016-07-20 | 2016-07-20 | Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180009993A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210039739A (en) * | 2019-10-02 | 2021-04-12 | (주)아모레퍼시픽 | Composition for enhancing skin elasticity or improving skin wrinkles |
-
2016
- 2016-07-20 KR KR1020160092024A patent/KR20180009993A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210039739A (en) * | 2019-10-02 | 2021-04-12 | (주)아모레퍼시픽 | Composition for enhancing skin elasticity or improving skin wrinkles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101176529B1 (en) | Cosmetic Composition Comprising the extract of Dendropanax morbifera as Active Ingredient | |
| KR101924956B1 (en) | Composition for Improving Skin Wrinkle Comprising Mugunghwa Extract Treated by Enzyme as an Active Ingredient | |
| KR20110076043A (en) | Cosmetic composition comprising smilax china as active ingredient | |
| KR102088728B1 (en) | Cosmetic Composition for Improving Skin Elasticity and Winkles Comprising Plant Complex Extracts as Active Ingredient | |
| KR101849661B1 (en) | Composition for Improving Skin Conditions Comprising Artemisia Princeps Pamp. Extract Treated by Enzyme as an Active Ingredient | |
| KR20180038639A (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| KR101754645B1 (en) | Composition for Preventing or Improving Skin Wrinkle Comprising Fermented Complex Extracts of Swallow's Nest as Active Ingredient, Patch, and Mask Pack Preventing or Improving Skin Wrinkle Using the Same | |
| KR101677460B1 (en) | Cosmetic composition comprising allergen removed water soluble royal jelly for skin whitening and anti-aging activity | |
| KR102544792B1 (en) | Composition Comprising Complex Extract of seaweeds Fermented by Lactobacillus Brevis with Anti-Wrinkling and Elasticity, Antioxidant, and Skin Hydration Property as Active Ingredient | |
| KR20180009991A (en) | Composition for improving elasticity and wrinkle of skin comprising Rhodiola rosea root extract treated by enzyme as active ingredient | |
| KR101877047B1 (en) | Composition for preventing or improving skin wrinkle comprising Eucalyptus globulus extract treated by enzyme as active ingredient | |
| KR20180009993A (en) | Composition for improving elasticity and wrinkle of skin comprising Euphrasia officinalis root extract treated by enzyme as active ingredient | |
| KR102176766B1 (en) | A cosmetic composition comprising subcritical water extracts of camellia sinensis | |
| KR20170110358A (en) | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng | |
| KR20200112130A (en) | Cosmetic composition for skin whitening comprising fermented Angelica gigas extract mixture as effective component | |
| KR20160093427A (en) | Cosmetic composition comprising the fermented extract of abeliophyllum distichum | |
| KR20190102364A (en) | Anti-aging composition and cosmetic using the same | |
| KR101877049B1 (en) | Composition for preventing or improving skin wrinkle comprising Angelica archangelica extract treated by enzyme as active ingredient | |
| KR101944494B1 (en) | Cosmetic composition comprising extract of Trachelospermum species comprising Trachelospermum jasminoides as active ingredient | |
| KR101984781B1 (en) | Cosmetic composition for improving whitening, wrinkle and elasticity of skin comprising persimmon byproduct extract produced by enzymatic hydrolysis and ultra high pressure homogenization as effective component | |
| KR20120118946A (en) | Skin whitening complex containing trihydroxyisoflavone and glycyrrhiza uralensis extracts | |
| KR101176525B1 (en) | Cosmetic Composition Comprising Acer tegmentosum Maxim as Active Ingredient | |
| KR101848647B1 (en) | A cosmetic composition comprising extracts of scapharca subcrenata | |
| KR101825178B1 (en) | Cosmetic composition comprising extract of dendropanax morbifera and d-asparatic acid with reinforced wrinkle elimanatin and whitening effect | |
| KR101991936B1 (en) | Composition for Preventing or Improving Skin Wrinkle Comprising Enzyme Treated Extract of Gastrodia as Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal |